GlassScriptPhysician profile
James Kirk Hartman
NPI 1194925198
$20,510.44
in general payments reported to CMS, 2019-2025
36 companies · $2,524 in 2025
The $2,524 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,204 · 2020: $2,620 · 2021: $4,553 · 2022: $3,745 · 2023: $2,553 · 2024: $2,310 · 2025: $2,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,351 · Education: $36.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,351.38 |
| Education | $36.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,262.00 | 2020-2025 | Caplyta |
| Abbvie INC. | $2,060.80 | 2021-2025 | |
| Lundbeck LLC | $1,838.59 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $1,599.95 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,457.87 | 2019-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,328.06 | 2019-2025 | Trintellix |
| Tris Pharma INC | $1,220.82 | 2019-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $939.63 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $885.21 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $847.90 | 2019-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $702.62 | 2020-2022 | |
| Corium, LLC | $615.73 | 2022-2024 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $475.96 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $446.90 | 2019-2020 | |
| Adlon Therapeutics L.P. | $435.53 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $373.50 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $349.22 | 2019-2025 | Uzedy |
| Bausch Health US, LLC | $343.95 | 2019-2025 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $328.21 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $286.72 | 2019 | |
| Alfasigma USA, INC. | $267.16 | 2020-2022 | |
| Axsome Therapeutics, INC. | $206.23 | 2022-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $201.55 | 2025 | Jornay Pm |
| Neuronetics, INC. | $192.69 | 2019-2024 | Neurostar Tms Therapy System |
| Shire North American Group INC | $145.26 | 2019 | |
| Indivior INC. | $134.84 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $114.04 | 2023-2024 | Quviviq |
| Boston Scientific Corporation | $101.33 | 2023-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, General - Therapies |
| Almatica Pharma LLC | $99.69 | 2024-2025 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $52.79 | 2019-2021 | |
| Orexo US, INC. | $45.12 | 2020 | |
| Arbor Pharmaceuticals, INC. | $40.24 | 2019 | |
| Vertical Pharmaceuticals, LLC | $39.84 | 2019-2020 | |
| Abbott Laboratories | $32.56 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $19.61 | 2022 | |
| Eisai INC. | $18.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.